| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christoph U Correll, Joan Zhao, William Carson, Ron Marcus, Robert McQuade, Robert A Forbes, Raymond Mankosk. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. Journal of the American Academy of Child and Adolescent Psychiatry. vol 52. issue 7. 2014-04-17. PMID:23800482. |
early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. |
2014-04-17 |
2023-08-12 |
Not clear |
| Steven G Potkin, Arash Raoufinia, Suresh Mallikaarjun, Patricia Bricmont, Timothy Peters-Strickland, William Kasper, Ross A Baker, Anna Eramo, Raymond Sanchez, Robert McQuad. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Current medical research and opinion. vol 29. issue 10. 2014-04-07. PMID:23822566. |
safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. |
2014-04-07 |
2023-08-12 |
Not clear |
| Xiao-Cong Zuo, Shi-Kun Liu, Zhi-Yong Yi, Zhi-Hong Xie, Huan-De L. Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. Current therapeutic research, clinical and experimental. vol 67. issue 4. 2014-03-28. PMID:24678101. |
steady-state pharmacokinetic properties of aripiprazole 10 mg po g12h in han chinese adults with schizophrenia: a prospective, open-label, pilot study. |
2014-03-28 |
2023-08-12 |
Not clear |
| Xiao-Cong Zuo, Shi-Kun Liu, Zhi-Yong Yi, Zhi-Hong Xie, Huan-De L. Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. Current therapeutic research, clinical and experimental. vol 67. issue 4. 2014-03-28. PMID:24678101. |
the aims of this study were to investigate the pharmacokinetic (pk) properties of aripiprazole in the steady state in han chinese adults with schizophrenia and to compare them between han chinese and white populations described in the literature. |
2014-03-28 |
2023-08-12 |
Not clear |
| John M Kane, Raymond Sanchez, Joan Zhao, Anna R Duca, Brian R Johnson, Robert D McQuade, Anna Eramo, Ross A Baker, Timothy Peters-Stricklan. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of medical economics. vol 16. issue 7. 2014-03-03. PMID:23663091. |
hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. |
2014-03-03 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Mariam Hassan, Ken O'Day, Kellie Meyer, Fred Grossma. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics. vol 16. issue 7. 2014-03-03. PMID:23701260. |
cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. |
2014-03-03 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Mariam Hassan, Ken O'Day, Kellie Meyer, Fred Grossma. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics. vol 16. issue 7. 2014-03-03. PMID:23701260. |
compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the us who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. |
2014-03-03 |
2023-08-12 |
Not clear |
| Andrea Cipriani, Simone Accordini, Michela Nosè, Marianna Purgato, Francesca Girlanda, Michele Tansella, Corrado Barbu. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. Journal of clinical psychopharmacology. vol 33. issue 4. 2014-02-18. PMID:23775051. |
aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. |
2014-02-18 |
2023-08-12 |
Not clear |
| Guillaume Legrand, Richard May, Barbara Richard, Mélanie Kernisant, Isabelle Jalenque. A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia. Journal of clinical psychopharmacology. vol 33. issue 4. 2014-02-18. PMID:23775055. |
a case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia. |
2014-02-18 |
2023-08-12 |
Not clear |
| Hiroyoshi Takeuchi, Gary Remingto. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology. vol 228. issue 2. 2014-02-10. PMID:23736279. |
a systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. |
2014-02-10 |
2023-08-12 |
Not clear |
| Hiroyoshi Takeuchi, Gary Remingto. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology. vol 228. issue 2. 2014-02-10. PMID:23736279. |
numerous case reports have suggested that aripiprazole can worsen psychotic symptoms in schizophrenia. |
2014-02-10 |
2023-08-12 |
Not clear |
| Mahima Panigrahi, Susanta Kumar Padhy, Rajesh Rath. Aripiprazole monotherapy in an adolescent worsens psychosis. Indian journal of pharmacology. vol 45. issue 2. 2014-01-23. PMID:23716902. |
aripiprazole, a partial agonist of dopamine and a second generation antipsychotic, has been approved specifically for treatment of children with schizophrenia of aged 13-17 years. |
2014-01-23 |
2023-08-12 |
Not clear |
| Yinbo Zhang, Guangzhi Da. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Human psychopharmacology. vol 27. issue 6. 2014-01-21. PMID:24446539. |
efficacy and metabolic influence of paliperidone er, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in china. |
2014-01-21 |
2023-08-12 |
Not clear |
| Yinbo Zhang, Guangzhi Da. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Human psychopharmacology. vol 27. issue 6. 2014-01-21. PMID:24446539. |
there are no direct comparisons of paliperidone extended-release (er), aripiprazole and ziprasidone in efficacy and metabolic influence in patients with first-episode schizophrenia. |
2014-01-21 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Raymond Sanchez, Brian Johnson, Na Jin, Robert A Forbes, Robert McQuade, Ross A Baker, William Carson, John M Kan. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International clinical psychopharmacology. vol 28. issue 4. 2014-01-17. PMID:23615694. |
long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. |
2014-01-17 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Raymond Sanchez, Brian Johnson, Na Jin, Robert A Forbes, Robert McQuade, Ross A Baker, William Carson, John M Kan. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International clinical psychopharmacology. vol 28. issue 4. 2014-01-17. PMID:23615694. |
the aim of this study was to evaluate the safety and tolerability of aripiprazole once-monthly (ari-om) for the maintenance treatment of schizophrenia. |
2014-01-17 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Raymond Sanchez, Brian Johnson, Na Jin, Robert A Forbes, Robert McQuade, Ross A Baker, William Carson, John M Kan. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International clinical psychopharmacology. vol 28. issue 4. 2014-01-17. PMID:23615694. |
ari-om had a safety and tolerability profile comparable with oral aripiprazole in maintenance treatment of schizophrenia. |
2014-01-17 |
2023-08-12 |
Not clear |
| Sergio De Filippis, Ilaria Cuomo, Luana Lionetto, Delfina Janiri, Maurizio Simmaco, Matteo Caloro, Simone De Persis, Gioia Piazzi, Alessio Simonetti, C Ludovica Telesforo, Antonio Sciarretta, Federica Caccia, Giovanna Gentile, Georgios D Kotzalidis, Paolo Girard. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. vol 33. issue 6. 2013-12-27. PMID:23505124. |
to assess acute efficacy and safety of 9.75 mg of intramuscular (im) injections of the atypical antipsychiatric aripiprazole in patients with schizophrenia or bipolar disorder and acute agitation. |
2013-12-27 |
2023-08-12 |
Not clear |
| Yutaro Suzuki, Takuro Sugai, Naoki Fukui, Junzo Watanabe, Shin Ono, Nobuto Tsuneyama, Mami Saito, Toshiyuki Somey. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Human psychopharmacology. vol 28. issue 3. 2013-12-18. PMID:23553637. |
we examined sex differences in the effect of olanzapine (olz), risperidone (ris), aripiprazole (arp), or quetiapine (qtp) on mean corrected qt (qtc) intervals among 222 patients with schizophrenia. |
2013-12-18 |
2023-08-12 |
Not clear |
| Farha Bilal Motiwala, Kim Stasia Siscoe, Rif S El-Mallak. Review of depot aripiprazole for schizophrenia. Patient preference and adherence. vol 7. 2013-11-22. PMID:24265550. |
review of depot aripiprazole for schizophrenia. |
2013-11-22 |
2023-08-12 |
Not clear |